Results 41 to 50 of about 15,404 (212)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells

Biomolecules, 2023
Cholesterol efflux is a major atheroprotective function of high-density lipoproteins (HDLs) which removes cholesterol from the foam cells of lipid-rich plaques in Type 2 diabetes.
Tomohiro Komatsu, Satomi Abe, Shihoko Nakashima, Kei Sasaki, Yasuki Higaki, Keijiro Saku, Shin-ichiro Miura, Yoshinari Uehara   +7 more
doaj   +1 more source

Versatile Palladium‐Catalyzed C‐H Arylation of Fluoroarenes with 2‐Chloropyridine Derivatives

Chemistry – A European Journal, EarlyView.
Direct C─H arylation of fluoroarenes with 2‐chloropyridines is enabled by a simple Pd/SPhos system in isopropyl acetate. The method uses inexpensive reactants and shows broad scope and high yields. DFT computations explain reactivity and selectivity.
Federico Belnome, Péter P. Fehér, András Stirling, Csongor G. Németh, Tamás Hergert, György M. Keserű, Péter Ábrányi‐Balogh   +6 more
wiley   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

, 2007
AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin ...
Fanurik, D, Sitagliptin Study 035 Group, Kipnes, M, Hermansen, K, Khatami, H, Stein, P, Luo, E   +6 more
core   +1 more source

The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin

Biology, 2019
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a beneficial class of antidiabetic drugs. However, a major debate about the risk of developing pancreatitis is still existing.
Lamiaa M. Shawky, Ahmed A. Morsi, Eman El Bana, Safaa Masoud Hanafy   +3 more
doaj   +1 more source

Sitagliptin ameliorates busulfan-induced pulmonary and testicular injury in rats through antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects

Scientific Reports, 2023
Busulfan (BUS) is an anticancer agent with serious adverse effects on various body organs, including the lung and testis. Sitagliptin was proven to have antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects.
Eman A. Ali, Sara G. Tayel, Mona A. Abbas   +2 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

SITAGLIPTIN- A COMPREHENSIVE REVIEW

, 2023
Sitagliptin is an orally administered, potent, and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes.
Pavankumar Wankhade*, Shraddha Suryawanshi, Deepti Waghmare
core   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source